332 related articles for article (PubMed ID: 24682103)
1. Unravelling the prostate-specific antigen controversy: a West of Scotland perspective.
Zafar N; Miller S; Leburn V; Qureshi KN; Rajan P
Scott Med J; 2014 May; 59(2):126-9. PubMed ID: 24682103
[TBL] [Abstract][Full Text] [Related]
2. Urologists' personal feelings on PSA screening and prostate cancer treatment.
Wenzler DL; Rosenberg BH
J Eval Clin Pract; 2014 Aug; 20(4):408-10. PubMed ID: 24798149
[TBL] [Abstract][Full Text] [Related]
3. Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden.
Pilebro B; Johansson R; Damber L; Damber JE; Stattin P
Scand J Urol Nephrol; 2003; 37(3):210-2. PubMed ID: 12775278
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
Bunting PS; Goel V; Williams JI; Iscoe NA
CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer.
Hayat Roshanai A; Nordin K; Berglund G
Acta Oncol; 2013 Nov; 52(8):1602-8. PubMed ID: 23421929
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark.
Jønler M; Eddy B; Poulsen J
Scand J Urol Nephrol; 2005; 39(3):214-8. PubMed ID: 16118092
[TBL] [Abstract][Full Text] [Related]
8. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
9. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
10. The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.
Frånlund M; Carlsson S; Stranne J; Aus G; Hugosson J
BJU Int; 2012 Sep; 110(5):638-43. PubMed ID: 22540895
[TBL] [Abstract][Full Text] [Related]
11. Practice patterns of urologists in managing Korean men aged 40 years or younger with high serum prostate-specific antigen levels.
Yoo DS; Woo SH; Cho S; Kang SH; Kim SJ; Park SY; Lee SH; Jeon SH; Park J
Urology; 2014 Jun; 83(6):1339-43. PubMed ID: 24726151
[TBL] [Abstract][Full Text] [Related]
12. Screening for prostate cancer: a comparison of urologists and primary care physicians.
McKnight JT; Tietze PH; Adcock BB; Maxwell AJ; Smith WO; Nagy MC
South Med J; 1996 Sep; 89(9):885-8. PubMed ID: 8790311
[TBL] [Abstract][Full Text] [Related]
13. Practitioner-level determinants of inappropriate prostate-specific antigen screening.
Kerfoot BP; Holmberg EF; Lawler EV; Krupat E; Conlin PR
Arch Intern Med; 2007 Jul; 167(13):1367-72. PubMed ID: 17620529
[TBL] [Abstract][Full Text] [Related]
14. Case-control prostate cancer screening studies should not exclude subjects with lower urinary tract symptoms.
Godley PA; Carpenter WR
J Clin Epidemiol; 2007 Feb; 60(2):176-80. PubMed ID: 17208124
[TBL] [Abstract][Full Text] [Related]
15. Baseline prostate-specific antigen testing at a young age.
Loeb S; Carter HB; Catalona WJ; Moul JW; Schroder FH
Eur Urol; 2012 Jan; 61(1):1-7. PubMed ID: 21862205
[TBL] [Abstract][Full Text] [Related]
16. Landmarks in prostate cancer screening.
Schröder FH
BJU Int; 2012 Oct; 110 Suppl 1():3-7. PubMed ID: 23046034
[TBL] [Abstract][Full Text] [Related]
17. [Focus on the screening for prostate cancer by PSA].
Roumeguère T; Van Velthoven R
Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
[TBL] [Abstract][Full Text] [Related]
18. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
19. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
[TBL] [Abstract][Full Text] [Related]
20. Screening for prostate cancer with PSA testing: current status and future directions.
Croswell JM; Kramer BS; Crawford ED
Oncology (Williston Park); 2011 May; 25(6):452-60, 463. PubMed ID: 21717898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
